1. PHAM Before the First Course Stem Cells Treatment (before)
Before the first stem cells treatment, PHAM can not walk and stand. Cerebral Palsy.
By: Cells Center China
Original post:
1. PHAM Before the First Course Stem Cells Treatment (before) - Video
Rejection... is it a problem with stem cell arthritis treatment?
http://www.stemcellsarthritistreatment.com Stem cells may not be rejected... here #39;s why it #39;s important for arthritis treatment... Ryan and colleagues in an a...
By: Nathan Wei
See the original post here:
Rejection... is it a problem with stem cell arthritis treatment? - Video
Stem Cell Therapy for Traumatic Brain Injury
Oswaldo Tapenes received multiple injections of human umbilical cord-derived mesenchymal stem cells and his own bone marrow-derived stem cells over the cours...
By: http://www.cellmedicine.com
See original here:
Stem Cell Therapy for Traumatic Brain Injury - Video
stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india short
improvement seen in just 6 months after stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done date 26th Mar...
By: Neurogen Brain and Spine Institute
Go here to see the original:
stem cell therapy treatment for cerebral palsy by dr alok sharma, mumbai, india short - Video
stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india short
improvement seen in just 4 months after stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india. Stem Cell Therapy done date 2nd ...
By: Neurogen Brain and Spine Institute
The rest is here:
stem cell therapy treatment for spinal cord injury by dr alok sharma, mumbai, india short - Video
stem cell therapy treatment for Quadriplegic Cerebral Palsy by dr alok sharma, mumbai, india short
improvement seen in just 3 months after stem cell therapy treatment for quadriplegic cerebral palsy by dr alok sharma, mumbai, india. Stem Cell Therapy done ...
By: Neurogen Brain and Spine Institute
stem cell therapy treatment for stroke by dr alok sharma, mumbai, india short
improvement seen in just 3 months after stem cell therapy treatment for stroke by dr alok sharma, mumbai, india. Stem Cell Therapy done date 23rd Jul 2013 Af...
By: Neurogen Brain and Spine Institute
Go here to see the original:
stem cell therapy treatment for stroke by dr alok sharma, mumbai, india short - Video
Stemcell treatment for hair and skin, Autologous Adipose Stem Cell Treatment
Through the history of stem cell therapy and stem cell research, animal stem cells have been used, human embryonic stem cells, and now research has led us to...
By: Ojas Aesthetic
See the original post here:
Stemcell treatment for hair and skin, Autologous Adipose Stem Cell Treatment - Video
Orange County, California (PRWEB) December 16, 2013
Top California stem cell clinic, TeleHealth, is now offering stem cell injections for plantar fasciitis. The condition may lead to chronic pain and may not respond to traditional treatments, with the stem cell therapy often allowing for pain relief and the ability to avoid the need for surgery. For more information and scheduling, call (888) 828-4575.
Planter fasciitis affects millions of Americans. The condition leads to chronic heel pain and may make it difficult to participate in recreational activities and even walk normally. Traditional treatments such as physical therapy, NSAIDS, steroid injections and orthotics are often effective over time. However, the condition may not respond as desired to these options and stem cells for plantar fasciitis may be the answer.
Therefore, stem cell injections that TeleHealth provides may offer an excellent option for healing the inflamed area while at the same time providing considerable pain relief. The conventional pain management treatments tend to mask pain, however, they do not actually heal the condition directly.
Regenerative medicine treatments with stem cells maintain the potential of actually healing the damaged tissue to provide long term relief. Telehealth has multiple US Board Certified doctors who have a long history of providing stem cell therapy for numerous conditions including degenerative arthritis, rotator cuff and Achilles tendonitis, ligament injury, elbow soft tissue tendinitis and more.
For those suffering from planter fasciitis or any of the other arthritic or soft tissue injury conditions, call TeleHealth at (888) 828-4575.
Link:
West Coast Stem Cell Clinic, Telehealth, Now Offering Stem Cell Injections for Plantar Fasciitis
Phoenix, Arizona (PRWEB) December 16, 2013
The top Phoenix stem cell treatment clinic, Arizona Pain Stem Cell Institute, is now offering stem cell therapy for plantar fasciitis. The treatments are offered by Board Certified pain management doctors in Arizona, and often help patients avoid surgery. For more information and scheduling, call (602) 507-6550.
Plantar fasciitis affects millions of Americans, causing heel pain that may make it difficult to participate in recreational activities and walking in general. Conventional treatments such as steroid injections, NSAIDS, bracing and physical therapy at times do not relieve the pain properly. Surgery for plantar fasciitis unfortunately does not always provide the desired relief.
Regenerative medicine at the Arizona Pain Stem Cell Institute offers a nonoperative option for plantar fasciitis. This may include stem cell injections with bone marrow, fat derived or amniotic derived material. The procedure is outpatient and low risk.
In addition to treatments for plantar fasciitis, the Institute offers stem cell treatments for degenerative arthritis, tennis elbow, rotator cuff symptoms, achilles tendonitis and more. The procedures are performed by Board Certified pain doctors, with four research projects ongoing.
The Institute is a division of Arizona Pain Specialists, the leading pain center in Arizona. Five locations accept over 50 insurance plans including Workers Compensation, Personal Injury, PPO's, some HMO's and self pay. The regenerative medicine treatments are offered as fee for service.
For more information and scheduling to discuss plantar fasciitis options, call (602) 507-6550.
Read more here:
Arizona Pain Stem Cell Institute Now Offering Stem Cell Therapy for Plantar Fasciitis
Thomas K. Sees Results After One Stem Cell Treatment! Stem Cells Can Help Stroke Patients!
Dr. David Steenblock treated patient Thomas K. with stem cells and instantly sees miraculous results. Stem cell treatments are helping stroke patients/victim...
By: David Steenblock
More:
Thomas K. Sees Results After One Stem Cell Treatment! Stem Cells Can Help Stroke Patients! - Video
By Dalia Dangerfield, Reporter Last Updated: Saturday, December 14, 2013, 8:48 PM TAMPA --
USF researchers believe stem cell therapy can help men and women with mild brain injuries.
This is quite a phenomenal observation, said Dr. Cesar Borlongan, a neuroscientist from USF Health. In our hands, stem cell therapy may offer this hope for the soldiers to prevent the progression of the disease and hopefully we can stop the disease process at the early stage."
In a recent study Borlongan injected adult stem cells in rats with traumatic brain injury. The stem cells served as a bridge, allowing new brain cells to move up to the damaged part of the brain.
That's a new concept, it's like the cells are very smart, said Borlongan.
Over time the adult stem cells helped partially repair the brain damage in rats.
Professor Borlongan believes the same may be true for humans allowing them to slowly get better.
Go here to read the rest:
New study shows stem cell therapy helps brain injuries
PUBLIC RELEASE DATE:
12-Dec-2013
Contact: Shaun Mason smason@mednet.ucla.edu 310-206-2805 University of California - Los Angeles
Stem cell researchers from UCLA have published the first study to identify the origin cells and track the early development of human articular cartilage, providing what could be a new cell source and biological roadmap for therapies to repair cartilage defects and damage from osteoarthritis.
Such transformative therapies could reach clinical trials within three years, said the scientists from UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research.
The study, led by Dr. Denis Evseenko, an assistant professor of orthopedic surgery and head of UCLA's Laboratory of Connective Tissue Regeneration, was published online Dec. 12 in the journal Stem Cell Reports and will appear in a forthcoming print edition.
Articular cartilage, a highly specialized tissue formed from cells called chondrocytes, protects the bones of joints from forces associated with load-bearing and impact and allows nearly frictionless motion between the articular surfaces the areas where bone connects with other bones in a joint.
Cartilage injury and a lack of cartilage regeneration often lead to osteoarthritis, which involves the degradation of joints, including cartilage and bone. Osteoarthritis currently affects more than 20 million people in the U.S., making joint-surface restoration a major priority in modern medicine.
While scientists have studied the ability of different cell types to generate articular cartilage, none of the current cell-based repair strategies including expanded articular chondrocytes or mesenchymal stromal cells from adult bone marrow, adipose tissue, sinovium or amniotic fluid have generated long-lasting articular cartilage tissue in the laboratory.
For the current study, Evseenko and his colleagues used complex molecular biology techniques to determine which cells grown from embryonic stem cells, which can become any cell type in the body, were the progenitors of cartilage cells, or chondrocytes. They then tested and confirmed the growth of these progenitor cells into cartilage cells and monitored their growth progress, observing and recording important genetic features, or landmarks, that indicated the growth stages of these cells as they developed into the cartilage cells.
Continue reading here:
UCLA stem cell scientists first to track joint cartilage development in humans
Poway, California (PRWEB) December 13, 2013
Noni is a ten-year-old released Canine Companion for Independence dog who just achieved her Master Agility Champion status after the pain from arthritis tried to slow her down. Nonis owner, Dr. Kim Dembinski, a veterinarian at Paradise Veterinary Hospital in San Diego turned to stem cell therapy by Vet-Stem, Inc. and fellow colleague Dr. Jennipher Harris to help Noni.
When Dr. Dembinski noticed weakness and discomfort in her aging agility dog she was proactive in keeping Noni happy and comfortable, The main thought was that she gives so much between therapy work, being my best friend, and as the clinic mascot that giving her relief from pain and her being more comfortable was the least I could do for her.
Nonis stem cell therapy involved a small fat sample collection, which was brought to Vet-Stems lab in Poway, California. There, highly trained lab technicians processed Nonis fat tissue to isolate the stem cells into doses that could be injected into the arthritic joints that were causing her pain. Normally the tissue is shipped overnight to Vet-Stem and the cells are shipped overnight back to the veterinarian making doses available within 48 hours, but because Paradise Veterinary Hospital is located near Vet-Stem Nonis stem cell doses were available for injection the same day the fat sample was collected.
Noni did very well post procedure; she regained muscle strength and flexibility, Dr. Dembinski reported, Noni did four weeks of rehab then went right back to competing in agility. Six months after the procedure she earned her MACH (Master Agility Champion), AKC (American Kennel Club) title. Because of her stem cell therapy she is still comfortable and playing agility!
Dr. Dembinski is a general practitioner for pets including dogs, cats, small mammals, birds and exotics. She is currently owner and primary veterinarian at Paradise Veterinary Hospital and sits on the board of the San Diego County Veterinary Medical Association. Caring for animals is not just a job for Dr. Dembinski, it is a passion. In her free time she and Noni compete in dog agility trials with AKC, North American Dog Agility Council and Canine Performance Events.
About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. The privately held company is working to develop therapies in veterinary medicine that apply regenerative technologies while utilizing the natural healing properties inherent in all animals. As the first company in the United States to provide an adipose-derived stem cell service to veterinarians for their patients, Vet-Stem, Inc. pioneered the use of regenerative stem cells in veterinary medicine. The company holds exclusive licenses to over 50 patents including world-wide veterinary rights for use of adipose derived stem cells. In the last decade over 10,000 animals have been treated using Vet-Stem, Inc.s services, and Vet-Stem is actively investigating stem cell therapy for immune-mediated and inflammatory disease, as well as organ disease and failure. For more on Vet-Stem, Inc. and Veterinary Regenerative Medicine visit http://www.vet-stem.com or call 858-748-2004.
Read more here:
San Diego Canine Overcomes Pain to Achieve Championship with the Help of Paradise Veterinary Hospital and Vet-Stem, Inc.
Contact Information
Available for logged-in reporters only
Newswise Stem cell researchers from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research have published the first study to identify the origin cells and track the early development of human articular cartilage, providing what could be a new cell source and biological roadmap for therapies to repair cartilage defects and osteoarthritis. These revolutionary therapies could reach clinical trials within three years.
Led by Dr. Denis Evseenko, assistant professor of orthopedic surgery and head of UCLAs Laboratory of Connective Tissue Regeneration, the study was published online ahead of print in Stem Cell Reports on December 12, 2013.
Articular cartilage is a highly specialized tissue formed from cells called chondrocytes that protect the bones of joints from forces associated with load bearing and impact, and allows nearly frictionless motion between the articular surfaces. Cartilage injury and lack of cartilage regeneration often lead to osteoarthritis involving degradation of joints, including cartilage and bone. Osteoarthritis currently affects more than 20 million people in the United States alone, making joint surface restoration a major priority in modern medicine.
Different cell types have been studied with respect to their ability to generate articular cartilage. However, none of the current cell-based repair strategies including expanded articular chondrocytes or mesenchymal stromal cells from adult bone marrow, adipose tissue, sinovium or amniotic fluid have generated long-lasting articular cartilage tissue in the laboratory.
By bridging developmental biology and tissue engineering, Evseenkos discoveries represent a critical missing link providing scientists with checkpoints to tell if the cartilage cells (called chondrocytes) are developing correctly.
We began with three questions about cartilage development, Evseenko said, we wanted to know the key molecular mechanisms, the key cell populations, and the developmental stages in humans. We carefully studied how the chondrocytes developed, watching not only their genes, but other biological markers that will allow us to apply the system for the improvement of current stem cell-based therapeutic approaches.
This research was also the first attempt to generate all the key landmarks that allow generation of clinically relevant cell types for cartilage regeneration with the highest animal-free standards. This means that the process did not rely on any animal components, thus therapeutic products such as stem-cell serums can be produced that are safe for humans.
Evseenko added that in a living organism more than one cell type is responsible for the complete regeneration of tissue, so in addition to the studies involving generation of articular cartilage from human stem cells, he and his team are now trying different protocols using different combinations of adult progenitor cells present in the joint to regenerate cartilage until the best one is found for therapeutic use.
Excerpt from:
UCLA Scientists First to Track Joint Cartilage Development in Humans
Contact Information
Available for logged-in reporters only
Newswise Scientists from UCLAs Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research are bringing stem cell science funded by the California Institute of Regenerative Medicine (CIRM), the state stem cell agency, directly to patients in two exciting new clinical trials scheduled to begin in early 2014. The recipients of the Disease Team Therapy Development III awards were Dr. Dennis Slamon and Dr. Zev Wainberg, whose phase I clinical trial will test a new drug that targets cancer stem cells and has been approved to begin enrolling patients in the US and Canada, and Dr. Donald Kohn, whose first-in-human trial is on stem cell gene therapy for sickle cell disease (SCD).
The announcement of the new awards came on December 12, 2013 at the meeting of the CIRM Independent Citizens Oversight Committee (ICOC) at the Luxe Hotel in Los Angeles. Dr. Owen Witte, Director of the UCLA Broad Stem Cell Research Center, highlighted that the The CIRM support demonstrates that our multidisciplinary Center is at the forefront of translating basic scientific research to new drug and cellular therapies that will revolutionize medicine.
Targeting solid tumor stem cells The Disease Team III grant to Dr. Dennis Slamon and Dr. Zev Wainberg and their US-Canadian collaborative team will support the first in human clinical trial scheduled to open in early 2014. The project builds on Dr. Slamons previous work partially funded by CIRM to develop a drug that targets tumor initiating cells with UCLAs Dr. Zev Wainberg, assistant professor of hematology/oncology and Dr. Tak Mak, director, Campbell Family Institute of the University Health Network in Toronto, Canada. Dr. Slamon, renowned for his research that led to the development of Herceptin, the first FDA-approved targeted therapy for breast cancer, is the director of clinical and translational research at the UCLA Jonsson Comprehensive Cancer Center, and professor, chief and executive vice chair for research in the division of hematology/oncology.
With investigational new drug approval from the Food and Drug Administration (FDA) and Health Canada, the Canadian governments therapeutic regulatory agency, this trial is an international effort to bring leading-edge stem cell science to patients.
We are delighted to receive this CIRM grant that will drive our translational research from the laboratory to the clinic, Slamon said, and allow us to test our targeted drug in a phase I clinical trial.
The trial is based on the evidence built over the last decade for what has become known as the cancer stem cell hypothesis. According to this hypothesis, cancer stem cells are the main drivers of tumor growth and are also resistant to standard cancer treatments. One view is that cancer stem cells inhabit a niche that prevents cancer drugs from reaching them. Another view is that tumors can become resistant to therapy by a process called cell fate decision, by which some tumor cells are killed by therapy and others become cancer stem cells. These cancer stem cells are believed to be capable of self-renewal and repopulation of tumor cells, resulting in the recurrence of cancer.
The target of the new drug is an enzyme in cancer stem cells and tumor cells called Polo-like kinase 4, which was selected because blocking it negatively affects cell fate decisions associated with cancer stem cell renewal and tumor cell growth, thus stopping tumor growth.
This potential anti-cancer drug is now ready to be tested in humans for the first time. Our goal is to test this novel agent in patients in order to establish safety and then to proceed quickly to rapid clinical development. We are excited to continue this academic collaboration with our Canadian colleagues to test this drug in humans for the first time, said Wainberg. Drs. Slamon, Wainberg, Mak and colleagues will also look for biological indications, called biomarkers, that researchers can use to tell if and how the drug is working.
Excerpt from:
UCLA Scientists Taking Stem Cell Research to Patients
Human Embryonic Stem Cells
By: 1someotherperson
Continue reading here:
Human Embryonic Stem Cells - Video
Update: Clinical Trials Using Stem Cells for Treatment of ALS at Mayo Clinic
Dr. Tony Windebank, Director of ALS trials at Mayo Clinic in Rochester, and Dr. Nathan Staff provide an update on clinical trials that are currently going on...
By: Mayo Clinic
See original here:
Update: Clinical Trials Using Stem Cells for Treatment of ALS at Mayo Clinic - Video
Embracing Regenerative Medicine within the #FutureOfHealthCare
From the 2013 World Stem Cell Summit, Dr. Andre Terzic, director of the Mayo Clinic Center for Regenerative Medicine talks about how Mayo Clinic has embraced...
By: Mayo Clinic
See the original post:
Embracing Regenerative Medicine within the #FutureOfHealthCare - Video
Regenerative medicine and Stem cells Partnering Terms and Agreements
Regenerative medicine and Stem cells Partnering Terms and Agreements Report @ http://www.reportsnreports.com/reports/219403-regenerative-medicine-and-stem-ce...
By: Paul Nelson
See more here:
Regenerative medicine and Stem cells Partnering Terms and Agreements - Video